News

October 2, 2018

Boehringer Buys ViraTherapeutics’ Shares to Expand Oncolytic Virus Program

News

Boehringer Ingelheim has bought all ViraTherapeutics’ shares, acquiring the company’s oncolytic virus platform and treatment candidates. The deal totaled €210 million (almost $247 million), and was based on a stock option agreement that ... Read more

September 28, 2018September 28, 2018

Imfinzi Prolongs Overall Survival in Advanced NSCLC Patients, Phase 3 Trial Data Show

News

Treatment with Imfinzi (durvalumab) significantly prolongs overall survival among patients with stage III, inoperable non-small-cell lung cancer (NSCLC) in comparison to those given a placebo, according to new data from ... Read more

September 26, 2018September 26, 2018

First Patient Dosed in Phase 1/2 Trial Assessing CBT-101 Combos in Liver, Kidney Cancers

News

CBT Pharmaceuticals has dosed the first participant in its Phase 1/2 clinical trial assessing the safety and tolerability of CBT-101, in combination with PD-1 inhibitors, in advanced or metastatic hepatocellular carcinoma (HCC) and ... Read more

September 25, 2018September 25, 2018

FDA Grants Priority Review to Keytruda as First-line Therapy for Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has agreed to review Merck‘s application seeking the extension of Keytruda (pembrolizumab) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). The ... Read more

September 21, 2018

Keytruda Granted Priority Review by FDA for Treatment of Merkel Cell Carcinoma

News

The U.S. Food and Drug Administration granted priority review to Merck’s supplemental Biologics License Application seeking accelerated approval for Keytruda (pembrolizumab) as a treatment for adults and children with recurrent locally ... Read more

September 19, 2018September 19, 2018

Bavencio-Inlyta Combo Therapy Delays Disease Progression or Death in Advanced Renal Cell Carcinoma Study

News

A combination of Bavencio (avelumab) and Inlyta (axitinib) significantly extends the time to disease progression or death in patients with untreated, advanced renal cell carcinoma (RCC), according to top-line results of a ... Read more

September 18, 2018September 18, 2018

Targeting Tumor Microenvironment Could Improve Response to Immunotherapies in Urothelial Cancer, Study Finds

News

The cells that support tumors — generally called stromal cells — play a significant part in the resistance to immune checkpoint inhibitor therapies seen in some urothelial cancers, according to a new ... Read more

September 14, 2018September 14, 2018

Keytruda and Chemotherapy Combo Now 1st-Line Treatment for Advanced NSCLC in EU

News

The European Commission approved the use of Keytruda (pembrolizumab), in combination with Alimta (pemetrexed) and platinum-based chemotherapy, as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). The approval is for ... Read more

September 12, 2018September 12, 2018

‘Switchable’ CAR T-cell Therapy Kills Advanced Pancreatic Cancer Cells in Mice, Study Reports

News

A “switchable” CAR T-cell immunotherapy was able to completely eliminate cancer in mice whose tumors came from cells of people with advanced pancreatic cancer, including cancer cells that had moved to ... Read more

September 11, 2018September 11, 2018

StemVacs Cancer Vaccine Shows Safety in Phase 1 Study and May Be Eligible for Right to Try, Therapeutic Solutions Says

News

StemVacs, a cell-based immunotherapy vaccine platform that targets cancer stem cells, was well-tolerated by 10 patients with multiple advanced cancers who took part in a Phase 1 safety trial, the ... Read more